Corporate Presentation Evercore ISI HealthCONx Conference December 3, 2020 Forward-looking Statements This presentation contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995 regarding, among other things, the design, initiation, timing and submission to the U.S. Food and Drug Administration (FDA) of a New Drug Application (NDA) for tebipenem HBr and the potential approval of tebipenem HBr by the FDA; future commercialization, the potential number of patients ...

PE Corporate Presentation Stifel Healthcare Conference November 18, 2020 Forward-looking Statements 2 This presentation contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995 regarding, among other things, the initiation, timing and submission to the U.S. Food and Drug Administration (FDA) of a New Drug Application (NDA) for tebipenem HBr and the potential approval of tebipenem HBr by the FDA; future commercialization, the potential number of patients who coul ...

Spero Therapeutics, Inc. (NASDAQ:SPRO) Q3 2020 Earnings Conference Call November 5, 2020 4:30 PM ET Company Participants Sharon Klahre – Vice President of Investor Relations and Strategic Finance Ankit Mahadevia – Chief Executive Officer David Melnick – Chief Medical Officer Cristina Larkin – Chief Operating Officer Steve DiPalma – Interim Chief Financial Officer Conference Call Participants Carvey Leung – Cantor Vishal Sethi – Cowen Ellen Sands – Stifel Operator Operator Good day, and welcome to the Spero ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2020 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38266 SPERO THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) ( State or other jurisdiction of inco ...

Spero Therapeutics, Inc. (NASDAQ:SPRO) Q2 2020 Earnings Conference Call August 6, 2020 4:30 PM ET Company Participants Sharon Klahre – Senior Director-Investor Relations Ankit Mahadevia – Co-Founder, President and Chief Executive Officer David Melnick – Chief Medical Officer Cristina Larkin – Chief Operating Officer Steve DiPalma – Interim Chief Financial Officer Conference Call Participants Ritu Baral – Cowen Louise Chen – Cantor Stephen Willey – Stifel Ram Selvaraju – H.C. Wainwright Chi Fong – Bank of Am ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Commission File Number: 001-38266 SPERO THERAPEUTICS, INC. Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2020 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to (Exact name of registrant as specified in its charter) ( State or other jurisdiction of incorpora ...

Corporate Presentation Bank of America Healthcare Conference May 13, 2020 Forward-looking Statements 2 This presentation contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995 regarding, among other things, the initiation, timing, progress and results of the Company's preclinical studies and clinical trials and its research and development programs, including management's assessment of such results; regulatory activities, including the Company's expectation th ...

Spero Therapeutics, Inc. (NASDAQ:SPRO) Q1 2020 Results Conference Call May 8, 2020 10:00 AM ET Company Participants Sharon Klahre - VP of IR and Strategy Dr. Ankit Mahadevia - Chief Executive Officer Dr. David Melnick - Chief Medical Officer Cristina Larkin - Chief Operating Officer Steve DiPalma - Interim Chief Financial Officer Conference Call Participants Louise Chen - Cantor Stephen Willey - Stifel Kevin DeGeeter - Oppenheimer Esther Hong - Janney Ram Selvaraju - H.C. Wainwright Chi Fong - Bank of Ameri ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2020 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38266 SPERO THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) ( State or other jurisdiction of incorpor ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2019 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ____to____ Commission file number 001-38266 SPERO THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) | Delaware | | 46-4590683 | | --- | --- ...